IBRXImmunityBio, Inc.
$8.22+225% 1Y
$8.22
$1.9852 weeks$11.55
Is the price fair?
What IBRX's price assumes
ImmunityBio, Inc. did not earn a profit over the last twelve months, so it has no trailing P/E and the price is measured against sales instead: 55.4× revenue.
55.4
Price / sales · no P/E: the last twelve months did not end in a profit
- EV / sales
- 55.8
EV / sales
Details›
- EV / EBIToperating margin −152%: the multiple describes the denominator
- not meaningful
- EV / salesas of 2026-Q2
- 55.8
- Market capitalisation1.06 billion shares, counted Jul 31, 2026
- $8.71B
Multiples from SEC filings and end-of-day closes; implied growth from a reverse discounted cash flow. Group medians across the names Ryufin tracks.
On our screens:Most shorted stocks